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Abstract
Background: Blood loss for laboratory testing may con-
tribute to hospital-acquired anemia. When implementing 
the core laboratory (core-lab) section, we consolidated 
first-line tests decreasing the number of tubes previously 
dispatched to different sites. Here, hypothesized benefits 
of the amount of blood volume drawn were explored.
Methods: We retrieved, using a laboratory information 
system (LIS), the number of tubes received by laborato-
ries interested in the change from all clinical wards in a 
year-based period, i.e. 2013 for pre-core-lab and 2015 for 
core-lab system, respectively. Data were expressed as the 
overall number of tubes sent to laboratories, the corre-
sponding blood volume, and the number of laboratory 
tests performed, normalized for the number of inpatients.
Results: After consolidation, the average number of blood 
tubes per inpatient significantly decreased (12.6 vs. 10.7, 
p < 0.001). However, intensive care units (ICUs) did not 
reduce the number of tubes per patient, according to the 
needs of daily monitoring of their clinical status. The 
average blood volume sent to laboratories did not vary 
significantly because serum tubes for core-lab required 
higher volumes for testing up to 55 analytes in the same 
transaction. Finally, the number of requested tests per 
patient during the new osystem slightly decreased (−2.6%).
Conclusions: Total laboratory automation does not auto-
matically mean reducing iatrogenic blood loss. The new 
system affected the procedure of blood drawing in clinical 
wards by significantly reducing the number of handled 
tubes, producing a benefit in terms of costs, labor and 
time consumption. Except in ICUs, this also slightly pro-
moted some blood saving. ICUs which engage in phleboto-
mizing patients daily, did not take advantage from the test 
consolidation.
Keywords: diagnostic blood loss; hospital-acquired 
anemia; total laboratory automation.
Introduction
Hospital-acquired anemia (HAA) is defined by a reduc-
tion of blood hemoglobin (Hb) concentrations in hos-
pitalized patients, in the absence of bleeding episodes 
occurring during the hospital stay [1, 2]. HAA worsens 
patient outcome, increasing morbidity and the likelihood 
of mortality, due to the exposure to nosocomial infec-
tions, immunological complications, thromboembolic 
events and the need for transfusions. Furthermore, HAA 
increases the length of hospitalization which reflects on 
the overall healthcare costs [3–5].
Although HAA etiology is usually multifactorial, one 
of the most important iatrogenic causes contributing to 
the decrease of Hb during hospitalization is the amount 
of blood collected for diagnostic testing [6–8]. Chronic 
phlebotomies during hospitalization may independently 
cause anemia [9]. In intensive care units (ICUs), the daily 
blood loss due to phlebotomy may range from 40 to 70 mL, 
accounting for 30% of the overall required transfusions 
[9–11]. However, Thomas et  al., found no association 
between anemia and phlebotomy practices when the 
daily volume of blood drawing per patient was kept 
around 25  mL [12]. The presence of specific diseases on 
hospital admission also increases the risk of developing 
HAA. For instance, patients hospitalized for acute myocar-
dial infarction may experience HAA, an indicator of poor 
outcome, both in-hospital and after discharge [13, 14]. 
The volume of blood phlebotomy may represent a strong 
predictor of anemia even in patients admitted to internal 
medicine departments in the absence of bleeding or other 
factors influencing Hb concentrations, with a 7 g/L esti-
mated drop in Hb for each 0.1 L of drawn blood [15].
The patient blood management multidisciplinary 
approach includes medical and surgical working strate-
gies based on clinical evidence, designed to maintain 
blood Hb concentrations at the physiological level, 
optimizing hemostasis and minimizing blood loss [16]. 
Accordingly, clinical laboratories should actively promote 
programs aimed at eliminating unnecessary blood loss 
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for diagnostic purpose [17]. Growing evidence underpins 
the pivotal role of clinical pathologists in driving clini-
cians towards appropriate laboratory test utilization [18]. 
Laboratory testing may aid in diagnosis, prognosis and 
establishment of treatment, but inappropriate requests 
of available tests can lead to overutilization [19, 20]. In 
the light of preventing HAA, guidance in test utilization 
to avoid inappropriate use may lead to lowering unnec-
essary phlebotomies. On the other hand, laboratories 
may request more blood than necessary, even when test 
requests are appropriate [21]. Blood collected for labo-
ratory purposes often exceeds the volume required by 
modern analyzers and therefore considerable amounts 
of blood are wasted [22–24]. The College of American 
Pathologists estimated a median blood draw of 2.76  mL 
for complete blood cell count (BCC) and 1.75 mL for elec-
trolyte panel, which corresponds to more than 8.5 and 12 
times the volume necessary for analysis, respectively [25]. 
On the other hand, the use of small volume samples may 
be challenging for the laboratory testing process [23]. For 
micro-collection, pediatric-sized tubes have technical and 
operational implications, because several analytical plat-
forms do not support them. In addition, they can be time 
and labor intensive, as reducing the blood volume may 
increase the risk of insufficient samples, requiring repeti-
tion of phlebotomy. Table  1 summarizes the main blood 
preservation strategies that are applicable at the labora-
tory and clinical ward levels.
In 2014, in our 600-bed metropolitan academic hos-
pital, we moved from a compartmentalized system toward 
a decision-making based laboratory department, set up 
as a core laboratory (core-lab), executing first-line tests 
from different disciplines, and satellite laboratory sec-
tions, performing specialized tests [26]. Supported by total 
laboratory automation (TLA) and information technology 
tools, our core-lab system has promoted optimal workload 
efficiency, with very short laboratory turnaround times for 
all results useful in first-line care [18, 26]. One of the most 
important changes in implementing the core-lab facility 
was the consolidation of first-line tests from different lab-
oratory subspecialties into a single section. Tests, which 
previously required different tubes for the analysis, were 
consolidated in a single tube moving among different 
core-lab platforms through a belt conveyor system (track). 
Despite the consolidation of tests imposed, the use of 
tubes warranting enough blood sample volume (5 mL) for 
the potential execution of all tests present in the menu on 
the same order, we pursued the advantage to pass from ten 
to three tubes, consolidating in one tube the testing for 55 
analytes in the serum and in another one two whole blood 
tests. Through the introduction of the TLA, we eliminated 
the concept of “urgent” tests, moving to a system where 
stat testing is not considered anymore, therefore reduc-
ing the risk for clinicians to duplicate test orders without 
affecting clinicians’ expectations in terms of timeliness of 
the laboratory service [27]. To the best of our knowledge, 
no studies have evaluated the impact of TLA implementa-
tion on diagnostic blood loss. Thus, in this study we did 
this evaluation, hypothesizing a reduction in the overall 
blood volume sent to the laboratory after the reorganiza-
tion for each patient during his/her hospitalization.
Materials and methods
Based on the panel of tests performed by the core-lab and, previously, 
by the compartmentalized laboratories of different specialties (i.e. 
chemistry, immunochemistry, hematology, microbiology, virology, 
etc.), we retrieved using the laboratory information system (LIS) the 
number of tubes received by the laboratories interested in the change 
from the all hospital clinical wards on a year-based period, i.e. 2013 
for the pre-core-lab and 2015 for the core-lab system, respectively. 
Samples sent by the Emergency Department were not included in the 
analysis because no substantial changes occurred for their dedicated 
order entry as well as in testing tube configuration (i.e. a heparin-
ized tube was used for a restricted test menu, defined according to 
a recent consensus [28]). Similarly, the dedicated tubes concerning 
Table 1: Strategies to minimize iatrogenic blood loss at laboratory and clinical ward levels.
Laboratory Clinical wards
Use of small collecting tubes Blood drawing only in the case of true clinical needs
Use of analytical platforms that require lower sample volume Appropriateness of test requests
Minimizing the amount of wasted samples Appropriate use of vascular catheters
Point-of-care testing Use of non-invasive monitoring systems
Elimination of obsolete tests Standardization of phlebotomy procedures
Implementation of local recommendations shared with the clinical staff Use of surgical technologies that can reduce blood loss
Application of “minimum retesting interval” rules
Alerting rules within a computerized provider order entry
Educational programs
Adapted from Ref. [8].
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cardiac markers (i.e. cardiac troponin and amino- terminal frag-
ment of type-B natriuretic peptide) were not included in the analysis 
because no changes occurred in the testing tube configuration and a 
dedicated pathway for these tests, not included in the TLA system, 
was in place [29]. The microtubes sent to the laboratory by the neo-
natology unit were also not included in the analysis.
The laboratory configuration in terms of tubes, sample types, 
blood volumes and tests performed during the two periods is 
reported in Table 2. The tests previously using heparinized plasma 
for stat determinations were consolidated in the serum tube for the 
core-lab, as serum represents the specimen of choice for immuno-
chemistry and microbiology assays.
Table 2: Laboratory system interested by the consolidation, with reference to testing tube types and filling volumes, performed tests and 
laboratories performing them in the pre-core laboratory period.
Sample (tube code)   Volume   Pre-core laboratory   Core laboratory
Serum (368966-BD)   3.5 mL  Clinical Pathology Unit, routine section: ALT, albumin, 
AST, total CO2, total bilirubin, conjugated bilirubin, 
calcium, chloride, HDL cholesterol, total cholesterol, 
cholinesterase, CK, creatinine, ALP, inorganic phosphate, 
GGT, glucose, iron, LDH, lipase, magnesium, potassium, 
CRP, sodium, transferrin, triglyceride, urate, urea
  –
Plasma (368884-BD)   4.0 mL  Clinical Pathology Unit, STAT section: ALT, AST, total 
bilirubin, conjugated bilirubin, calcium, chloride, 
CK, creatinine, phosphorous, glucose, LDH, lipase, 
magnesium, potassium, CRP, sodium, urea
  –
Serum (367957-BD)   3.5 mL  Clinical Pathology Unit, immunochemistry section: 
ferritin, total β-hCG
  –
Serum (368813-BD)   4.0 mL  Pharmacology Unit: digoxin   –
Serum (367957-BD)   3.5 mL  Endocrinology Unit: TSH, fT3, fT4   –
Serum (368968-BD)   5.0 mL  Microbiology and Virology Unit: HAV Ab IgG, HAV Ab 
IgM, anti-HBs Ab, anti-HBc Ab, anti-HBc Ab IgM, anti-
HBe Ab, HBe Ag, HBs Ag, HBs Ag qualitative, HCV Ab, 
HIV1/HIV2 Ag-Ab, treponema pallidum Ab
  –
Serum (367955-BD)   5.0 mL  Microbiology and Virology Unit: toxoplasma Ab IgG, 
toxoplasma Ab IgM, rubella Ab IgG, rubella Ab IgM, CMV 
IgG, CMV IgM, HSV 1-2 IgG, HSV 1-2 IgM, HSV-2 IgG
  –
Serum (368969-BD)   5.0 mL  –   ALT, albumin, AST, total CO2, total bilirubin, 
conjugated bilirubin, calcium, chloride, HDL 
cholesterol, total cholesterol, cholinesterase, 
CK, creatinine, ALP, inorganic phosphate, 
GGT, glucose, iron, LDH, lipase, magnesium, 
potassium, CRP, sodium, transferrin, 
triglyceride, urate, urea, ferritin, total β-hCG, 
digoxin, TSH, fT3, fT4, HAV Ab IgG, HAV Ab 
IgM, anti-HBs Ab, anti-HBc Ab, anti-HBc 
Ab IgM, anti-HBe Ab, HBe Ag, HBs Ag, HBs 
Ag qualitative, HCV Ab, HIV1/HIV2 Ag-Ab, 
treponema pallidum Ab, toxoplasma Ab IgG, 
toxoplasma Ab IgM, rubella Ab IgG, rubella 
Ab IgM, CMV IgG, CMV IgM, HSV 1–2 IgG, 
HSV 1–2 IgM, HSV-2 IgG
Whole blood 
(368857-BD)
  3.0 mL  Hematology Unit: blood cell count, reticulocytes   –
Whole blood 
(10200-Diesse)
  1.0 mL  Clinical Pathology Unit: Erythrocyte sedimentation rate   –
Whole blood 
(368857-BD)
  3.0 mL  –   Blood cell count, reticulocytes, erythrocyte 
sedimentation rate
Plasma (363048-BD)   2.7 mL  Hematology Unit: PT, aPTT, D-dimer, fibrinogen   PT, aPTT, D-dimer, fibrinogen
BD, Becton Dickinson; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; ALP, alkaline phosphatase; GGT, 
γ-glutamyltransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein; hCG, human chorionic gonadotropin; TSH, thyroid-stimulating 
hormone, fT3, free triiodothyronine; fT4, free thyroxine; HAV, hepatitis A virus; Ab, antibody; Ag, antigen; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; CMV, cytomegalovirus; HSV, herpes simplex virus; PT, prothrombin time; aPTT, activated partial thromboplastin time.
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We included in the analysis all samples sent to laboratories for 
the two study periods that were assayed for at least one of the listed 
tests. We estimated the total blood volume sent to laboratories by 
multiplying the sample numbers by the filling volume of the respec-
tive tubes. Further, the number of tests performed by laboratories 
for the two study periods were retrieved from the LIS and grouped 
according to the sample type. The analysis was done by considering 
the different wards of our institution, grouped according to the type 
of clinical subspecialty when appropriate, e.g. medical wards were 
grouped as “medicine” and surgical wards grouped as “surgery”. Our 
institution is specialized in the setting of infectious diseases and this 
clinical area was treated independently from the others.
Data were expressed as the overall number of inpatient tubes sent 
to laboratories, the corresponding blood volume, and the number of 
performed laboratory tests, normalized for the number of inpatients. 
The same normalization was done in the analysis dedicated to the 
different clinical wards of the hospital. Further, we performed a spe-
cific analysis for samples related to biochemistry/immunochemistry/
microbiology tests: data were expressed as number of patient tubes 
sent to laboratories, the corresponding blood volume, and number of 
performed laboratory tests, normalized for the number of inpatients 
for different clinical wards. Statistical significance in the differences 
between the two periods was assessed using the χ2 (chi)-square test.
Results
Table 3 shows the number of collected blood sample tubes 
and performed tests in the two study periods, together 
with the corresponding blood volume drawn per patient 
during hospitalization. The test consolidation due to 
the implementation of the core-lab facility allowed to 
decrease the total number of blood tubes per patient sent 
to the laboratory during their hospitalization (−1.9 tubes 
in average). As expected according to the test integration 
pursued with the core-lab system, the largest decrease 
was charged to tubes for biochemistry/immunochemis-
try/microbiology tests (−21.9%) and, to a lesser extent, to 
those for BCC/erythrocyte sedimentation rate (ESR) anal-
ysis (−5.2%). No changes were seen for coagulation tubes 
for which no modification between the two periods was 
in fact planned. The difference in the overall number of 
blood samples sent to the laboratory after the normaliza-
tion for the number of inpatients hospitalized in the two 
study periods was statistically significant (p < 0.001).
The total blood volume sent to laboratories did not 
vary significantly between the two periods (p = 0.85). The 
use of a single blood sample for core-lab potentially per-
mitted to test up to 55 analytes in the same transaction 
requested enough sample volume, i.e. 5 mL, to perform 
all tests and, if needed, retest individual results in case 
of critical values, inconsistency with clinical condition, 
etc. This evidently nullified, in terms of the amount 
of blood drawn, the advantage of test consolidation, 
described in Table 2, when the core-lab was begun. The 
blood saved with the incorporation of ESR in the BCC 
EDTA testing tube was low (−1.2%). The main reasons are 
two, ESR is not often requested and the testing tube in 
the pre-corelab had 1 mL of filling volume. Accordingly 
Table 3: Number of collected blood samples and performed tests in the two study periods, and the corresponding blood volume drawn per 
patient during his/her hospitalization.
  Pre-core laboratory  Core laboratory  Post vs. pre, %  p-Value
No. of patients   14,696  15,301  605 (+4.1%) 
Number of blood tubes
  Biochemistry/immunochemistry/serology   80,876  63,189  −17,687 (−21.9%) 
 BCC/ESR   67,223  63,734  −3489 (−5.2%) 
 Coagulation tests   37,251  36,932  −319 (−0.9%) 
 Total   185,350  163,855  −21,495 (−11.6%) 
  Samples per patient   12.6  10.7  −1.9 (−15%)  <0.001
Blood volume, mL
  Biochemistry/immunochemistry/serology   319,383  315,945  −3438 (−1.1%) 
 BCC/ESR   193,469  191,202  −2267 (−1.2%) 
 Coagulation tests   100,578  99,716  −861 (−0.9%) 
 Total   613,429  606,863  −6566 (−1.1%) 
  Volume per patient   41.7  39.7  −2 (−4.8%)  0.85
Number of tests
  Biochemistry/immunochemistry/serology   578,334  591,105  12,771 (+2.2%) 
  BCC/ESR   66,672  67,535  863 (+1.3%) 
 Coagulation tests   93,079  89,117  −3962 (−4.3%) 
 Total   738,085  747,757  9672 (+1.3%) 
 Test per patient   50.2  48.9  −1.3 (−2.6%)  0.019
BCC, blood cell count; ESR, erythrocyte sedimentation rate.
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the overall blood saved after the consolidation of the 
test in the tube for BCC was not relevant and poorly con-
tributed in the slight decrease of the overall diagnostic 
blood loss observed and reported in Table  2. The nor-
malization of data to the number of patients showed a 
small decrease in the mean volume of blood drawn per 
patient during hospitalization (−2 mL). Even the number 
of tests per patient performed during the new system 
slightly decreased (−1.3 in average) (p = 0.019).
Table 4 shows the findings from the most important 
clinical wards. The ICUs were the only wards that did not 
reduce the number of tubes per patient after the core-lab 
activation, according to the need of daily monitoring of the 
clinical status of patients with severe illness and/or mul-
tiple organ dysfunction. On the contrary, the infectious 
disease department reduced the average number of tubes 
per patient (from 20 to 16.5), although keeping unchanged 
(91.2 vs. 91.0) the average number of tests performed in 
their patients during hospitalization, often lasting many 
days while caring for acute infections and their comor-
bidities. Overall, data reported in Table 4 indicate that the 
new laboratory system seems to promote a slight optimi-
zation of blood drawing, with a reduction in the number 
of collected tubes per patient. However, ICUs, which phle-
botomized patients daily, did not receive any advantage 
from the test consolidation. Given that intensivists did not 
change their standards of care, the daily ordering of the 
same tests with a higher volume of blood (up to 1.5  mL 
more) according to the core-lab system resulted in a slight 
increase of blood volume sent to the laboratory.
We also investigated the impact derived from the 
change of an order entry system from the pre-core-
lab era, characterized by duplicated entries (stat and 
ordinary) for a list of first-line tests, used differently 
depending on the expectation of timeliness of result 
delivery, toward a TLA system, where only one order 
entry is available and no more stat testing is consid-
ered. Table 5 shows results related to tubes for bio-
chemistry/immunochemistry/serology tests, which are 
those mostly affected by the organizational changes. 
These changes allowed to consistently save samples 
for all clinical wards, except for ICUs. In general, this 
resulted in a decrease of blood volume per hospital-
ized patient (from 2.2  mL in Medicine and Infectious 
Disease Departments to 6  mL in Cardiology). The col-
lected blood volume remained unchanged in Surgery, 
even if the number of tests per patients decreased from 
43.4 to 36.3. As no changes were introduced in the local 
guidelines for preoperative tests, we can infer that, at 
least for these types of wards, the change in laboratory 
system reduced the duplication of ordered tests. Ta
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Discussion
In the recent years, the consolidation of laboratory tests 
in a core-lab has been promoted in light of financial ben-
efits it gives and to maximize efficiency [30]. Laboratory 
specialists have, however, the opportunity to be proactive 
in clinically optimizing these operational efficiencies [18]. 
We previously described how this change from a com-
partmentalized laboratory department to a consolidated 
laboratory activity may provide the occasion to create a 
decision-making-based laboratory department, where 
the core-lab should include first-line tests, with all the 
results reported in a clinically effective turnaround time, 
and satellite laboratories executing specialized tests [26].
Within a core-lab project, the consolidation of many 
tests in a single tube represents a potential tool to promote 
patient safety and to improve clinical outcome, throughout 
the management of diagnostic blood loss. During hospitali-
zation, patients are exposed to repeated blood collections 
for laboratory testing, therefore increasing their suscepti-
bility to develop anemia. Vincent et al. established a signifi-
cant relationship between the severity of organ dysfunction 
and the volume of blood drawn in critically ill patients [31]. 
In our core-lab setting, driven by clinical governance, we 
consolidated first-line tests previously performed in differ-
ent laboratories in single tubes for the same sample (i.e. 
serum, plasma and whole blood), carried through a belt 
conveyor from one analyzer to another one. The main aim 
of this study was to evaluate the impact of this reorganiza-
tion on the blood volume sent to the laboratory.
In general, the configuration of tubes implemented in 
our core-lab (described in Table 2) did not allow reaching a 
marked decrease in the blood volume drawn during patient 
hospitalization. Despite the incorporation of 55 tests in a 
single serum tube, the use of 5-mL tubes, needed for the 
determination of all serum analytes in the same order if 
requested, affected the total volume of blood sent to the 
laboratory, limiting the blood saving that was expected by 
us after the laboratory reorganization. Except for ICUs, the 
saved volume corresponded to the amount of blood usually 
needed to collect one/two samples (2.5–5.3 mL), which may 
correspond to one phlebotomy less per patient. This indi-
cates that the new system promoted a slight optimization 
of blood drawing in most clinical wards. Other possible 
alternatives were possible: for instance, the option using 
two tubes of 3.5 mL, for chemistry-immunochemistry and 
for virology, would add one tube per patient, but possibly 
reduce blood loss for the repeated chemistry tests during a 
long length of stay in hospital. However, our initial choice 
was to consolidate in only one tube as many tests as pos-
sible and then to evaluate the impact of this choice even on 
the amount of blood drawn. Some data did not sufficiently 
meet our expectations; we reported data, for example, for 
patients admitted to Infectious Disease wards, who expe-
rienced longer time of hospitalization due to clinical com-
plications or difficulties in diagnosis but who were not 
daily phlebotomized, showing a tendency in blood saving 
according to our selected approach.
Our data show that ICUs had no advantage in blood 
saving after the changes introduced with core-lab imple-
mentation. This subset of hospitalized patients is tightly 
monitored for life-threatening conditions, by assaying basic 
tests, such as metabolic markers (e.g. electrolytes) or tests 
indicating organ and system dysfunctions (e.g. creatinine), 
which are ordered in a standard way, often daily, regardless 
of order entry system. They are seldom interested in order-
ing the full menu of tests consolidated in our core-lab tubes. 
Thus, the reorganization moving, for example, for serum/
plasma biochemistry from 3.5/4-mL to 5-mL tubes may para-
doxically worsen the situation of the requested blood volume 
per patient. For ICUs patients, we also showed a moderate 
increase (in average, +5.6) in the number of tests requested 
during hospitalization after laboratory consolidation.
With the change of order entries, where stat requests 
were eliminated, we observed a reduction in the overall 
number of tubes per patient sent to laboratory, especially 
for biochemistry tests (from 5.5 to 4.1). Ialongo et al. [27], 
previously showed that the elimination of a dedicated 
stat path by TLA implementation may produce a decrease 
of duplicated test requests. Although our study was not 
primarily designed to prove the effect of TLA introduc-
tion on test duplication, we have seen similar effects only 
in surgery wards, where in the previous system the stat 
path was probably adopted to anticipate some laboratory 
results related to vital parameters.
Our study has some limitations. Firstly, we consid-
ered all inpatients for whom at least one blood sample 
was sent to the laboratories interested in changes in the 
system, regardless to their length of stay, which represents 
one of the factors influencing the onset of HAA. Further-
more, patients may move to others wards during their 
hospitalization according to their changes in clinical con-
ditions or occurrence of medical complications, and this 
may also influence the evaluated parameters. Secondly, 
we only accounted for the blood volumes related to the 
tests involved in the core-lab implementation, but clini-
cal wards also sent blood to laboratories for other inves-
tigations. For instance, the amount of blood collected 
for microbial blood culture amounts to a 10  mL bottle 
[32]. Accordingly, the impact on the diagnostic blood loss 
related to the change in our system cannot be directly 
translated to the risk of HAA.
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Conclusions
In a previous publication, we described our laboratory 
department model, in which the short turnaround time for 
all first-line tests performed by TLA in the core-lab represents 
the key paradigm, where no more stat testing is required 
because all samples are handled in real-time and (auto)
validated results are dispatched in a time that fulfils clinical 
needs [26]. Here we evaluated the impact of this model on 
the diagnostic blood loss and the number of ordered tests. 
As expected, our system affected the procedure of blood 
drawing in the clinical wards by significantly reducing the 
number of handled tubes, reasonably producing a benefit 
in terms of costs, labor and time consumption. Except in 
ICUs, this also slightly promoted blood saving. Although 
the statistical analysis showed no significant difference in 
volume of collected blood per ICU patient in the two studied 
periods, our experience suggests that great attention should 
be paid in the selection of tube size when test consolidation 
is planned, in order to fit the optimal balance between the 
number of orderable tests, the availability of enough sample 
volume to perform them, and the corresponding blood loss. 
In particular, the samples tubes should be selected accord-
ing to the intended users in order not to affect subjects for 
whom repeated phlebotomies for a reduced panel of tests 
are required. Our study helped to identify this subset with 
patients hospitalized in ICUs, the group more prone to 
become anemic during hospitalization. For these subjects, 
dedicated strategies should be further implemented to 
promote blood saving and avoid HAA, even in the TLA era.
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